Physician profile
Mitchell Haut
NPI 1023015674
$3,780.41
in general payments reported to CMS, 2019-2025
53 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,279 · 2020: $788 · 2021: $689 · 2022: $24.99.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $414.55 | 2019-2021 | |
| Celgene Corporation | $231.00 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $210.80 | 2019-2020 | |
| Genentech USA, INC. | $200.81 | 2019 | |
| Eisai INC. | $194.22 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $193.04 | 2019-2021 | |
| Amgen INC. | $163.77 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $158.45 | 2019-2020 | |
| Genzyme Corporation | $145.40 | 2019-2021 | |
| Clovis Oncology, INC. | $132.33 | 2019-2020 | |
| Janssen Biotech, INC. | $125.06 | 2019-2021 | |
| Glaxosmithkline, LLC. | $112.58 | 2020-2022 | |
| Amag Pharmaceuticals, INC. | $110.35 | 2019-2021 | |
| Lilly USA, LLC | $108.04 | 2019-2021 | |
| Puma Biotechnology, INC. | $98.95 | 2019-2021 |
Show all 47 companies
6 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Haut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.